Christine Bokman, MD
Ophthalmology · Naples, FLNPI 1710374814
Payments from drug & device makers
Across 247 payments — averaging $250.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$55K
- Alcon$2K
- Merz North America, Inc.$2K
- AbbVie$430
- Sight Sciences, Inc.$302
- Johnson & Johnson Vision Care, Inc.$250
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,0632%
- Speaking & faculty fees$44,65572%
- Travel & lodging$4,5627%
- Food & beverage$11,59319%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 146 | $54,625 |
| Alcon | 25 | $2,490 |
| Merz North America, Inc. | 24 | $1,750 |
| AbbVie(2 entities) | 16 | $430 |
| Sight Sciences, Inc. | 3 | $302 |
| Johnson & Johnson Vision Care, Inc. | 2 | $250 |
| Bausch & Lomb Americas Inc. | 2 | $248 |
| Revance Therapeutics, Inc. | 8 | $235 |
| Tarsus Pharmaceuticals, Inc. | 3 | $188 |
| Galderma Laboratories, L.p. | 4 | $175 |
| Glaukos Corporation | 1 | $166 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $164 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Novartis | 1 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $125 |
| Sun Pharmaceutical Industries Inc. | 1 | $121 |
| Rxsight Inc | 1 | $119 |
| Ocular Therapeutix, Inc. | 1 | $109 |
| Oyster Point Pharma, Inc. | 2 | $45 |
| Dompe US, Inc. | 1 | $28 |
| Halozyme Inc | 1 | $25 |
| Lumenis, Inc | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$49,711
- AcrySof$1,427
- XEOMIN$721
- PanOptix$253
- Acuvue$250
- iStent inject Trabecular Micro-Bypass Stent System$166
- TOTAL30$146
- Clareon$125
- EYLEA$125
- MIEBO$125
- DURYSTA$125
- XDEMVY$125
- STELLARIS PC$125
- INFUSE$123
- BIOTRUE ONE DAY$123
- OMNI(R) SURGICAL SYSTEM (US)$122
- CEQUA$121
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$119
- DEXTENZA$109
How this compares
$61,887 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 657 | $6,503 |
| Cephalexin | 41 | $828 |
| Methylprednisolone | 64 | $413 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $263 |
| ErythromycinErythromycin Base | 16 | $149 |
| Mupirocin | 19 | $120 |
| Lorazepam | 14 | $8 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Naples
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.